INSYS Therapeutics Announces Addition of VP of Marketing to Commercial Team

PHOENIX, AZ--(Marketwire - December 05, 2011) - INSYS Therapeutics (PINKSHEETS: NEOL) announces the addition of Matthew Napoletano as Vice President of Marketing to their commercial product team. He will lead the strategic and tactical marketing initiatives in preparation for the launch of INSYS’ breakthrough cancer pain product candidate, Subsys® fentanyl sublingual spray.

Matt is a highly accomplished Marketing Executive and brings more than 15 years of industry experience in the areas of both marketing and sales to INSYS. Matt has played a lead role in the commercialization of multiple products and line extensions in the areas of pain management/supportive care, women’s health, diagnostic imaging and radiopharmaceuticals. Most recently at Cephalon, Inc. (Teva Pharmaceuticals) Matt led the launch of pain products and built strategic relationships with thought leaders. Prior to that, Matt led the launch of products and line extensions at Berlex Laboratories (Bayer) and completed a corporate development rotation at parent company Schering, AG in Berlin, Germany. Matt holds a BS Degree from Shippensburg University and is currently enrolled in the Pharmaceutical & Healthcare Marketing Executive MBA program at St. Joseph’s University.

Michael Babich, President and CEO of INSYS, adds, “We are delighted to add an individual with such depth in the area of pain management and supportive care to our team as we continue to expand our commercial focus.”

About INSYS Therapeutics, Inc.

INSYS Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative products that address chemotherapy-induced nausea and vomiting (CINV), pain management and other central nervous system disorders. We develop new formulations and delivery methods for existing drugs in order to achieve enhanced efficacy, faster onset of action, reduced side effects, convenient delivery and increased patient compliance. Our drug development programs are based on existing compounds with known or proven safety, efficacy and commercialization histories. We are focused on leveraging our expertise in the expanding synthetic cannabinoid derivatives and specialized opioid markets to build a portfolio of proprietary products that address the limitations of existing therapies.